Sensitization by interleukin-1α of carboplatinum anti-tumor activity against human ovarian (NIH:OVCAR-3) carcinoma cells in in vitro and in vivo

International Journal of Cancer

Volumn 68, Issue 5, 1996, Pages 583-587

  Wang, Zheng ^a   Lee, Kang Bo ^a   Reed, Eddie ^a   Sinha, Birandra K ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; INTERLEUKIN 1ALPHA; ANTINEOPLASTIC AGENT; INTERLEUKIN 1; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; TUMOR CELL LINE; ANIMAL; CANCER TRANSPLANTATION; CARCINOMA; CELL CULTURE; DRUG RESISTANCE; EXPERIMENTAL NEOPLASM; FEMALE; NUDE MOUSE; OVARY TUMOR;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; HUMANS; INTERLEUKIN-1; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; OVARIAN NEOPLASMS; RECOMBINANT PROTEINS; TUMOR CELLS, CULTURED;

EID: 0029658443     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19961127)68:5<583::AID-IJC5>3.0.CO;2-V     Document Type: Article

References (22)

1. BENCHEKROUN, M.N., PARKER, R., REED, E. and SINHA, B.K., Inhibition of DNA repair and sensitization of cisplatin in human ovarian carcinoma cells by interleukin-1α. Biochem. biophys. Res. Comm., 195, 294-300 (1993).
2. BRAUNSCHWEIGER, P.G., JOHNSON, C.S., KUMAR, N., ORD, V. and FURMANSKI, P., Antitumor effects of recombinant human interleukin la in RIF-1 and Panc02 solid tumors. Cancer Res., 48, 6011-6016 (1988).
3. CHANG, M.-J., Yu, W.D., REYNO, L.M., MODEZLEWSKI, R.A., EGORIN, M.J., ERKMEN, K., VLOCK, D.R., FURMANSKI, P. and JOHNSON, C.S., Potentiation by interleukin 1 of cisplatin and carboplatin antitumor activity: schedule-dependence and pharmacokinetics in the RIF-1 tumor model. Cancer Res., 54, 5380-5386 (1994).
4. CHOU, T.-C. and TALALAY, P., Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul., 22, 27-55 (1983).
5. EPPSTEIN, D.A., KURAHARA, C.G., BRUNO, N.A. and TERRELL, T.G., Prevention of doxorubicin-induced hepatotoxicity in mice by interleukin-1. Cancer Res., 49, 3955-3960 (1988).
6. 15N]-nitrate in biological fluids. Anal. Biochem., 126, 131-138 (1982).
7. HAMILTON, T.C., YOUNG, R.C., MCKOY, K.R., GREEN, J.A., CHU, E.W., WHANG-PENG, J., ROGAN, A.M., GREEN, W.R. and OZOLS, R.F., Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res., 43, 5379-5389 (1983).
8. KILBOURN, R.G. and BELLONI, P., Endothelial cell production of nitrogen oxide in response to interferon γ in combination with tumor necrosis factor, interleukin-1, or endotoxin. J. nat. Cancer Inst., 82, 772-776 (1990).
9. KILIAN, P.L., KAFFKA, K.L., BIONDI, D.A., LIPMAN, J.M., BENJAMIN, W.R., FELDMAN, D. and CAMPDEN, C.A., Antiproliferative effect of interleukin-1 on human ovarian carcinoma cell line (NIH:OVCAR-3). Cancer Res., 51, 1823-1828 (1991).
10. LE, J. and VILCEK, J., Biology of disease. Tumor necrosis factor and interleukin 1 : cytokines with multiple overlapping biological activities. Lab. Invest., 56, 234-248 (1987).
11. MATSUBARA, T. and ZIFF, M., Increased Superoxide release from human endothelial cell in response to cytokines. J. Immunol., 137, 3295-3298 (1986).
12. MIMNAUGH, E.G., MONTI, E., SEBERS, S., STETLER-STEVENSON, S. and SINHA, B.K., Synergistic antiproliferative effects of the combination of human interleukin-lα and doxorubicin against human melanoma cells. Oncol. Res., 4, 401-412 (1992).
13. MONTI, E., MIMNAUGH, E.G. and SINHA, B.K., Synergistic antiproliferative effects of interleukin-lα and doxorubicin against human ovarian carcinoma cell line. Biochem. Pharmacol., 45, 2099-2107 (1993).
14. NEHME, N., ALBIN, N., CALIARO, M.J., GUICHARD, S., JOZAN, S., JULIA, A.-M., BUGART, R. and CANAL, P., Mechanisms of interaction between cisplatin and human interferon gamma in human ovarian cancer cell lines. Int. J. Cancer, 29, 643-648 (1995).
15. ONOZAKI, K., MASTUSHIMA, K., AGGARWAL, B.B. and OPPENHEIM, J.J., Human interleukin-1 is a cytocidal factor for several tumor cell lines. J. Immunol., 135, 3962-3968 (1985).
16. PACIOTTI, G.F. and TAMARKIN, L., Interleukin-1 directly regulates hormone-dependent human breast cancer cell proliferation in vitro. Mol. Endocrinol., 2, 459-464 (1988).
17. PARKER, R.J., EASTMAN, A., BOSTIC-BRUTON, F. and REED, E., Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. J. clin. Invest., 87, 772-777 (1991).
18. REED, E. and KOHN, K.W., Platinum analogues. In: B.A. Chabner and J.M. Collins (eds.), Cancer chemotherapy: principle and practices, pp. 465-490, J.B. Lippincott, Philadelphia (1990).
19. REED, E., SAUERHOFF, S. AND POIRIER, M.C., Quantitation of platinum-DNA binding in human tissues following therapeutic levels of drug exposure. Atom. Spectro., 9, 93-96 (1988).
20. RICHON, V.M., SCHULTE, N. and EASTMAN, A., Multiple mechanisms of resistance to cis-diamminedichloroplatinum (II) in murine leukemia L1210 cells. Cancer Res., 47, 2056-2061 (1987).
21. USUI, N., MIMNAUGH, E.G. and SINHA, B.K., A role for the interleukin 1 receptor in the Synergistic antitumor effects of human interleukin-lα and etoposide against human melanoma cells. Cancer Res., 51, 769-774 (1991).
22. WANG, Z., BENCHEKROUN, M.N. and SINHA, B.K., Potentiation of antitumor activities of carboplatin and camptothecin by interleukin-lα against human ovarian carcinoma in vivo. Anticancer Res., 14, 1723-1726 (1994).